secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-05-14T20:19:13+00:00
Accession:  0001193125-26-224101
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma Q1 net loss $5.2M; appoints new CEO, $30M private placement, CUE-221 license
--------------------------------------------------------------------------------

- Net loss $5.2M ($1.08 EPS) vs $12.3M loss in Q1 2025; revenue $5.7M from Boehringer collaboration.
- Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO and Board Director.
- Completed $30M private placement (pre-funded and common warrants); received $7.5M milestone from Boehringer.
- Exclusive license for CUE-221 (Phase 2 anti-IgE) from Ascendant Health; IND amendment for food allergy expected H2 2026.
- Cash $16.4M at Mar 31, 2026; subsequent $30M private placement extends runway for clinical milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526224101/0001193125-26-224101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526224101/cue-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-224101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer